MX2008013212A - 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. - Google Patents

4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.

Info

Publication number
MX2008013212A
MX2008013212A MX2008013212A MX2008013212A MX2008013212A MX 2008013212 A MX2008013212 A MX 2008013212A MX 2008013212 A MX2008013212 A MX 2008013212A MX 2008013212 A MX2008013212 A MX 2008013212A MX 2008013212 A MX2008013212 A MX 2008013212A
Authority
MX
Mexico
Prior art keywords
csf
anilinoquinoline
carboxamides
kinase inhibitors
manufacture
Prior art date
Application number
MX2008013212A
Other languages
English (en)
Inventor
Thomas Gero
David Scott
Xiaolan Zheng
Donald Cook
Leslie Dakin
David Del Valle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2008013212A publication Critical patent/MX2008013212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La invención se refiere a compuestos químicos de fórmula IA o IB: fórmula IA o IB o sales farmacéuticamente aceptadas de los mismos que poseen actividad inhibitoria de la cinasa CFS-1R y son por consiguiente útiles para su actividad anticáncer y así en métodos de tratamiento del cuerpo humano o animal. La invención también se relaciona con procesos para la fabricación de compuestos químicos, a composiciones farmacéuticas que las contienen y con su uso en al fabricación de medicamentos de uso en la producción de un efecto anticáncer en un animal de sangre caliente tal como el hombre.
MX2008013212A 2006-04-14 2007-04-12 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. MX2008013212A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74485706P 2006-04-14 2006-04-14
US86509006P 2006-11-09 2006-11-09
PCT/GB2007/001338 WO2007119046A1 (en) 2006-04-14 2007-04-12 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2008013212A true MX2008013212A (es) 2008-10-22

Family

ID=38268859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013212A MX2008013212A (es) 2006-04-14 2007-04-12 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.

Country Status (28)

Country Link
US (1) US20090054411A1 (es)
EP (1) EP2010496B1 (es)
JP (1) JP2009533405A (es)
KR (1) KR20080112380A (es)
CN (1) CN101466682A (es)
AR (1) AR060508A1 (es)
AT (1) ATE478849T1 (es)
AU (1) AU2007238372A1 (es)
BR (1) BRPI0710191A2 (es)
CA (1) CA2649146A1 (es)
CY (1) CY1111203T1 (es)
DE (1) DE602007008710D1 (es)
DK (1) DK2010496T3 (es)
EC (1) ECSP088828A (es)
HK (1) HK1126199A1 (es)
HR (1) HRP20100580T1 (es)
IL (1) IL194424A0 (es)
MX (1) MX2008013212A (es)
NO (1) NO20084202L (es)
PL (1) PL2010496T3 (es)
PT (1) PT2010496E (es)
RS (1) RS51483B (es)
RU (1) RU2008144806A (es)
SI (1) SI2010496T1 (es)
TW (1) TW200808732A (es)
UY (1) UY30282A1 (es)
WO (1) WO2007119046A1 (es)
ZA (1) ZA200808599B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
US20110190272A1 (en) * 2008-05-07 2011-08-04 Astrazeneca Ab Chemical compounds
AR076766A1 (es) * 2009-05-14 2011-07-06 Japan Tobacco Inc Compuestos de azetidina, composiciones farmaceuticas y su uso en el tratamiento de enfermedades autoinmunes.
WO2012016082A1 (en) 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
JP2014504269A (ja) * 2010-11-05 2014-02-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 化学化合物
HUE032754T2 (en) * 2011-05-05 2017-10-30 Novartis Ag CSF-1R inhibitors for the treatment of brain tumors
WO2012151541A1 (en) * 2011-05-05 2012-11-08 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
TWI623536B (zh) * 2012-01-19 2018-05-11 腫瘤療法 科學股份有限公司 １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
JP6426194B2 (ja) 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109700794B (zh) * 2017-03-01 2021-01-08 浙江大学 腙结构类型雄激素受体拮抗剂及其应用
US20230382871A1 (en) * 2020-09-23 2023-11-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Csf1r kinase inhibitor and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
BR9914167B1 (pt) * 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
CN1144786C (zh) * 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US7598258B2 (en) * 2002-05-01 2009-10-06 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2005034955A1 (en) * 2003-09-15 2005-04-21 Wyeth Substituted quinolines as protein tyrosine kinase enzyme inhibitors
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1

Also Published As

Publication number Publication date
KR20080112380A (ko) 2008-12-24
CN101466682A (zh) 2009-06-24
HK1126199A1 (en) 2009-08-28
SI2010496T1 (sl) 2010-11-30
CA2649146A1 (en) 2007-10-25
WO2007119046A1 (en) 2007-10-25
AU2007238372A1 (en) 2007-10-25
DK2010496T3 (da) 2010-11-08
CY1111203T1 (el) 2015-06-11
PL2010496T3 (pl) 2011-01-31
TW200808732A (en) 2008-02-16
AR060508A1 (es) 2008-06-25
DE602007008710D1 (en) 2010-10-07
PT2010496E (pt) 2010-10-13
ATE478849T1 (de) 2010-09-15
BRPI0710191A2 (pt) 2012-06-05
JP2009533405A (ja) 2009-09-17
IL194424A0 (en) 2009-08-03
NO20084202L (no) 2008-10-08
RS51483B (en) 2011-04-30
RU2008144806A (ru) 2010-05-20
HRP20100580T1 (hr) 2010-11-30
ECSP088828A (es) 2008-11-27
EP2010496A1 (en) 2009-01-07
US20090054411A1 (en) 2009-02-26
ZA200808599B (en) 2009-11-25
UY30282A1 (es) 2007-11-30
EP2010496B1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
MX2009004908A (es) Compuestos quimicos.
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2007113558A8 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
MX2007008924A (es) Compuestos quimicos.
TW200736234A (en) Chemical compounds
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
TW200621259A (en) Chemical compounds
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
WO2009155121A3 (en) Inhibitors of pi3 kinase
TW200833663A (en) Therapeutic agents
TW200621730A (en) Chemical compounds
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
WO2009016410A3 (en) Chemical compounds 831
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration